Oral Supplements of Combined Zhengchangsheng® and Xylooligosaccharides Improve High-Fat Diet-Induced Obesity and Modulate the Gut Microbiota in Rats

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2020 Jun 9

PMID 32509874

Citations 12

Authors

Yuyuan Li

Man Liu

He Liu

Xiaoqing Wei

Xianying Su

Ming Li

Jieli Yuan

Affiliations

Soon will be listed here.

Abstract

Gut dysbiosis induced by high-fat diet (HFD) may result in low-grade inflammation leading to diverse inflammatory diseases. The beneficial effects of probiotics and prebiotics on obesity have been reported previously. However, their benefits in promoting human health and the underlying mechanisms still need to be further characterized. This study is aimed at understanding how probiotic Zhengchangsheng® (BL) and prebiotic xylooligosaccharides (XOS) influence the health of a rat model with HF (60 kcal %) diet-induced obesity. Five groups of male Sprague Dawley (SD) rats were fed a normal fat diet (CON) or an HFD with or without BL and XOS supplementation for 3 weeks. Lipid profiles, inflammatory biomarkers, and microbiota composition were analyzed at the end of the experiment. Rats fed an HFD exhibited increased body weight and disordered lipid metabolism. In contrast, combined BL and XOS supplementation inhibited body weight gain and returned lipid metabolism to normal. Furthermore, BL and XOS administration changed the gut microbiota composition and modulated specific bacteria such as , , and . In addition, supplements of combined BL and XOS obviously reduced the serum LPS level, which was significantly related to microbial variations. Our findings suggest that modulation of the gut microbiota as a result of probiotic BL and prebiotic XOS supplementation has a positive effect on HFD-induced obesity in rats.

Citing Articles

Exploring Therapeutic Advances: A Comprehensive Review of Intestinal Microbiota Modulators.

Pires L, Gonzalez-Paramas A, Heleno S, Calhelha R Antibiotics (Basel). 2024; 13(8).

PMID: 39200020 PMC: 11350912. DOI: 10.3390/antibiotics13080720.

Microbial-Based Bioactive Compounds to Alleviate Inflammation in Obesity.

Apalowo O, Adegoye G, Obuotor T Curr Issues Mol Biol. 2024; 46(3):1810-1831.

PMID: 38534735 PMC: 10969769. DOI: 10.3390/cimb46030119.

Effect of Continuous Ingestion of Bifidobacteria and Inulin on Reducing Body Fat: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study.

Baba Y, Saito Y, Kadowaki M, Azuma N, Tsuge D Nutrients. 2023; 15(24).

PMID: 38140284 PMC: 10745352. DOI: 10.3390/nu15245025.

Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota.

Flaig B, Garza R, Singh B, Hamamah S, Covasa M Nutrients. 2023; 15(1).

PMID: 36615885 PMC: 9823358. DOI: 10.3390/nu15010228.

Potential application of the probiotic as an adjuvant in the treatment of diseases in humans and animals: A systematic review.

Ramirez-Olea H, Reyes-Ballesteros B, Chavez-Santoscoy R Front Microbiol. 2022; 13:993451.

PMID: 36225361 PMC: 9549136. DOI: 10.3389/fmicb.2022.993451.

References

Beutler B, Rietschel E . Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol. 2003; 3(2):169-76. DOI: 10.1038/nri1004. View

Zhou A, Hergert N, Rompato G, Lefevre M . Whole grain oats improve insulin sensitivity and plasma cholesterol profile and modify gut microbiota composition in C57BL/6J mice. J Nutr. 2015; 145(2):222-30. DOI: 10.3945/jn.114.199778. View

Turnbaugh P, Ley R, Mahowald M, Magrini V, Mardis E, Gordon J . An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006; 444(7122):1027-31. DOI: 10.1038/nature05414. View

Liu Z, Wang N, Ma Y, Wen D . Hydroxytyrosol Improves Obesity and Insulin Resistance by Modulating Gut Microbiota in High-Fat Diet-Induced Obese Mice. Front Microbiol. 2019; 10:390. PMC: 6410680. DOI: 10.3389/fmicb.2019.00390. View

Delzenne N, Neyrinck A, Backhed F, Cani P . Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol. 2011; 7(11):639-46. DOI: 10.1038/nrendo.2011.126. View

Kverka M, Zakostelska Z, Klimesova K, Sokol D, Hudcovic T, Hrncir T . Oral administration of Parabacteroides distasonis antigens attenuates experimental murine colitis through modulation of immunity and microbiota composition. Clin Exp Immunol. 2010; 163(2):250-9. PMC: 3043316. DOI: 10.1111/j.1365-2249.2010.04286.x. View

Anhe F, Nachbar R, Varin T, Vilela V, Dudonne S, Pilon G . A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss. Mol Metab. 2017; 6(12):1563-1573. PMC: 5699918. DOI: 10.1016/j.molmet.2017.10.003. View

Barbier de La Serre C, Ellis C, Lee J, Hartman A, Rutledge J, Raybould H . Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010; 299(2):G440-8. PMC: 2928532. DOI: 10.1152/ajpgi.00098.2010. View

. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2001; 894:i-xii, 1-253. View

10.

Sakamoto M, Benno Y . Reclassification of Bacteroides distasonis, Bacteroides goldsteinii and Bacteroides merdae as Parabacteroides distasonis gen. nov., comb. nov., Parabacteroides goldsteinii comb. nov. and Parabacteroides merdae comb. nov. Int J Syst Evol Microbiol. 2006; 56(Pt 7):1599-1605. DOI: 10.1099/ijs.0.64192-0. View

11.

Bibbo S, Ianiro G, Dore M, Simonelli C, Newton E, Cammarota G . Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2018; 2018:9321643. PMC: 5833468. DOI: 10.1155/2018/9321643. View

12.

De Maesschalck C, Eeckhaut V, Maertens L, De Lange L, Marchal L, Nezer C . Effects of Xylo-Oligosaccharides on Broiler Chicken Performance and Microbiota. Appl Environ Microbiol. 2015; 81(17):5880-8. PMC: 4551243. DOI: 10.1128/AEM.01616-15. View

13.

Baskin M, Ard J, Franklin F, Allison D . Prevalence of obesity in the United States. Obes Rev. 2005; 6(1):5-7. DOI: 10.1111/j.1467-789X.2005.00165.x. View

14.

Delzenne N, Cani P . Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr. 2011; 31:15-31. DOI: 10.1146/annurev-nutr-072610-145146. View

15.

Xi B, Liang Y, He T, Reilly K, Hu Y, Wang Q . Secular trends in the prevalence of general and abdominal obesity among Chinese adults, 1993-2009. Obes Rev. 2011; 13(3):287-96. PMC: 3276709. DOI: 10.1111/j.1467-789X.2011.00944.x. View

16.

Chakraborti C . New-found link between microbiota and obesity. World J Gastrointest Pathophysiol. 2015; 6(4):110-9. PMC: 4644874. DOI: 10.4291/wjgp.v6.i4.110. View

17.

Igel L, Saunders K, Fins J . Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction. Curr Atheroscler Rep. 2018; 20(8):39. DOI: 10.1007/s11883-018-0740-z. View

18.

Wang Z, Lam K, Hu J, Ge S, Zhou A, Zheng B . Chlorogenic acid alleviates obesity and modulates gut microbiota in high-fat-fed mice. Food Sci Nutr. 2019; 7(2):579-588. PMC: 6392816. DOI: 10.1002/fsn3.868. View

19.

Li Y, Liu M, Zhou J, Hou B, Su X, Liu Z . Zhengchangsheng® attenuates DSS-induced colitis and modulates the gut microbiota in mice. Benef Microbes. 2019; 10(5):543-553. DOI: 10.3920/BM2018.0122. View

20.

Duncan S, Louis P, Thomson J, Flint H . The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol. 2009; 11(8):2112-22. DOI: 10.1111/j.1462-2920.2009.01931.x. View